Healthcare

Medibank (ASX:MPL) reported group revenue from external customers of AUD 9,115.2 million for the year ended 30 June 2026, an increase of 5.9%. Group operating profit rose 6.7% to AUD 813.5 million. Underlying net profit after tax increased 2.9% to AUD 636.8 million, while …

For the six months ended 30 June 2026, Neuren Pharmaceuticals (ASX:NEU) reported total income of A$42.7 million, compared with A$39.7 million in the corresponding period. Royalty income from DAYBUE reached A$33.2 million (US$23.3 million), compared with A$28.3 million (US$18.1 million) a year earlier. These …

• The company holds Australian manufacturing and controlled-substance authorisations supporting regulatedSupplywithin the limits of its licences.

• The company announced the departure of Chief Commercialization Officer Tolga Tanguler, with a search for his successor underway

• Egetis' lead asset EMCITATE is the first and only approved treatment for peripheral thyrotoxicosis associated with MCT8 deficiency

• The company raised full-year 2026 revenue guidance to $460–$470 million, representing 51%–54% growth

• Procedure revenue declined 15.1% to $28.9 million, while dietary supplements revenue grew 7.3% to $12.0 million